HER2阳性乳腺癌脑转移吡咯替尼治疗中颅脑放疗时机的多中心真实世界队列研究
该多中心回顾性队列纳入101例接受颅脑放疗联合吡咯替尼的HER2阳性乳腺癌脑转移患者,按治疗顺序分为同期组、吡咯替尼进展后放疗组和放疗后进展用吡咯替尼组。中位随访43.3个月,三组间中位CNS-PFS和OS均无显著差异,但局灶性颅脑放疗与更长OS独立相关,毒性可控。
要点
- 治疗顺序未显著影响OS或CNS-PFS。
- 局灶性颅脑放疗与更长OS独立相关(HR 0.56)。
- 毒性总体可控,放射性坏死发生7例(6.9%)。
核心结论
- 颅脑放疗与吡咯替尼的治疗顺序未显著影响HER2阳性乳腺癌脑转移患者的OS或CNS-PFS。
- 局灶性颅脑放疗与更长OS独立相关,毒性可控。
- 探索性放疗时机阈值仅具假设生成意义,需前瞻性验证。
研究设计与样本
- 回顾性两中心真实世界队列研究,纳入101例HER2阳性乳腺癌脑转移患者,接受颅脑放疗联合吡咯替尼治疗(2018年6月至2025年7月)。
- 按治疗顺序分为三组:同期放疗与吡咯替尼组(A组,n=41)、吡咯替尼颅内进展后放疗组(B组,n=38)、放疗后进展使用吡咯替尼组(C组,n=22)。
- 主要终点为CNS-PFS,采用Kaplan-Meier法和Cox比例风险模型评估生存结局。
主要发现
- 中位随访43.3个月,63例(62.4%)死亡,70例(69.3%)发生CNS-PFS事件。
- 总体中位CNS-PFS为14.8个月(95%CI 10.68-19.92),A、B、C组分别为14.3、15.0、21.4个月(P=0.252)。
- 总体中位OS为36.0个月(95%CI 28.0-39.7),A、B、C组分别为33.0、35.4、42.0个月(P=0.281)。
- 局灶性颅脑放疗与更长OS独立相关(HR 0.56,95%CI 0.34-0.94;P=0.028)。
- 任何级别不良事件发生100/101例(99.0%);≥3级事件在A、B、C组分别为2.4%、7.9%、4.5%(所有P>0.05);放射性坏死7例(6.9%)。
关键数值与推荐
- 探索性阈值:放疗在吡咯替尼开始前>3.9个月与更长OS相关(49.9 vs 29.8个月;HR 0.31,95%CI 0.11-0.91;P=0.025),但未通过内部验证。
临床怎么用
- 对于HER2阳性乳腺癌脑转移,颅脑放疗与吡咯替尼的治疗顺序可根据临床情况选择,无需强制特定顺序。
- 局灶性颅脑放疗可能为患者带来更长OS,可优先考虑。
- 治疗期间需关注毒性,尤其是放射性坏死。
局限性
- 回顾性研究设计,样本量有限(101例)。
- 探索性放疗时机阈值未通过内部验证,需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Cranial radiotherapy (RT) and pyrotinib both demonstrate efficacy in HER2-positive breast cancer brain metastases (BCBM); however, the optimal sequencing of these modalities remains to be established. We evaluated survival across treatment sequences within a real-world cohort. MATERIALS AND METHODS: This retrospective, two-centre study included 101 patients with HER2-positive BCBM treated with cranial RT plus pyrotinib (June 2018-July 2025). Based on treatment sequence, patients were categorized into: concurrent RT and pyrotinib (Group A, n = 41); RT after intracranial progression on pyrotinib (Group B, n = 38); and pyrotinib upon progression following RT (Group C, n = 22). The primary endpoint was CNS-PFS. Survival outcomes were assessed via Kaplan-Meier estimation and Cox proportional hazards models. RESULTS: At a median follow-up of 43.3 months, 63 patients (62.4%) had died and 70 (69.3%) experienced CNS-PFS events. Median CNS-PFS was 14.8 months (95% CI 10.68-19.92) overall, and 14.3, 15.0, and 21.4 months in groups A, B, and C, respectively (P = 0.252); median OS was 36.0 months (95% CI 28.0-39.7) overall, and 33.0, 35.4, and 42.0 months in groups A, B, and C, respectively (P = 0.281). Focal cranial RT was independently associated with longer OS (HR 0.56, 95% CI 0.34-0.94; P = 0.028). Any-grade adverse events occurred in 100 of 101 patients (99.0%); grade ≥ 3 events occurred in 2.4%, 7.9%, and 4.5% of groups A, B, and C, respectively (all P > 0.05), and radiation necrosis occurred in 7 patients (6.9%). An exploratory threshold of RT initiated >3.9 months before pyrotinib (OS 49.9 vs 29.8 months; HR 0.31, 95% CI 0.11-0.91; P = 0.025) did not withstand internal validation. CONCLUSIONS: Treatment sequence did not significantly affect OS or CNS-PFS. Focal cranial RT was independently associated with longer survival, and toxicity was manageable. The proposed timing threshold is hypothesis-generating and warrants prospective validation.
引用
- Chen Z, Jing H, Huang S, et al. Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study. Clin Transl Radiat Oncol. 2026. PMID: 42927325. doi:10.1016/j.ctro.2026.101310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。